INSM
NASDAQ · Biotechnology
Insmed Inc
$98.61
+2.81 (+2.93%)
Performance
1D
—
1W
—
1M
—
3M
—
6M
-44.57%
1Y
-6.46%
YTD
-44.33%
Open$95.82
Previous Close$95.80
Day High$99.88
Day Low$95.27
52W High$212.75
52W Low$90.39
Volume—
Avg Volume6.63M
Market Cap20.76B
P/E Ratio—
EPS$-5.74
SectorBiotechnology
Technical Indicators
Full analysis →
SMA 50
$168.11
Below
SMA 200
$139.54
Below
RSI (14)
54.8
Neutral
Trend
Golden Cross
Bullish
Analyst Ratings
Strong Buy
29 analysts
Price Target
+45.4% upside
Current
$98.61
$98.61
Target
$143.40
$143.40
$91.17
$143.40 avg
$177.14
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 660.47M | 488.51M | 44.36B |
| Net Income | -1,390,575,496 | -925,678,954 | 1.08B |
| Profit Margin | -210.5% | -200.0% | 2.4% |
| EBITDA | -1,351,364,973 | -949,553,790 | 2.00B |
| Free Cash Flow | — | — | 843.11M |
| Rev Growth | +35.2% | +35.2% | +19.4% |
| Debt/Equity | 0.99 | 0.99 | 0.36 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $230.01 | +6.25% | 105.2 | 382.49B |
| AMGN | Amgen Inc | $344.72 | +2.11% | 23.4 | 182.21B |
| GILD | Gilead Sciences Inc | $124.87 | +0.90% | 16.7 | 153.66B |
| VRTX | Vertex Pharmaceuticals Inc | $466.79 | +3.36% | 26.4 | 114.63B |
| REGN | Regeneron Pharmaceuticals | $612.50 | +0.42% | 14.5 | 63.95B |
| ALNY | Alnylam Pharmaceuticals Inc | $286.41 | +2.99% | 64.3 | 37.13B |